---
title: "<span style='color:red;'>Treat-to-Target <br> <span class='small-vs'>vs</span> <br> High-intensity statin</span>"
subtitle: "_Randomised, open-label, non-inferiority trial<br> in CAD patients_" 
format: 
  revealjs:
    slide-number: true
    transition: slide
    theme: simple
    footer: LODESTAR
    reference-location: document
    scrollable: true
editor: visual
---

# [Previous Studies]{style="color:navy;"}

## [EMPATHY trial]{style="color:#FF6666;"}

### Interventions:

#### Intensive Therapy Group:

-   Target LDL-C levels below 70mg/dL

#### Standard Therapy Group:

-   Target LDL-C levels 100-120mg/dL

## [Takeaways]{style="color:#FF6666;"}

-   **Primary endpoint**: Intensive therapy **did not** significantly reduce CV event or death
-   **Secondary endpoint**: Intensive therapy did significantly reduce cerebral events
-   **Post-hoc analysis**: patients who achieved their LDL-C target of below 70 mg/dL showed a significant reduction in CV event

## [TST trial]{style="color:#FF6666;"}

### Interventions:

#### Intensive Therapy Group:

-   Target LDL-C levels below 70mg/dL

#### Standard Therapy Group:

-   Target LDL-C levels 100Â± 10 mg/dL.

## [Takeaways]{style="color:#FF6666;"}

### Primary endpoint
- Intenstive therapy group showed a significant reduction in major CV events
- Intensive therapy group showed a significant reduction in <br> ischemic stroke, MI, need for revascularization

# [Methods]{style="color:navy;"}

## [Study design]{style="color:#FF6666;"}

-   Multicenter
-   Randomized(_stratified by LDL\<100, ACS, DM_)
-   Secondary randomization: _rosuvastatin vs atorvastatin_
-   Open-label
-   Noninferiority trial

## [Procedure]{style="color:#FF6666;"}

#### Treat-to-Target Group: 
- _Statin-naive patient_: moderate-intensity statin 
- _Follow up_ <br>**Uptitration** when LDL-C\>70<br> **Down-titration** when LDL-C\<50 <br> else maintain

#### HIgh-intensity statin Group:
-   Maintenance of high-intensity statin recommended

## [Primary endpoint]{style="color:#FF6666;"}<br><br>
-   Major adverse cardiac event<br><br>
-   Major advers cerebrovascular event

## [Secondary endpoint]{style="color:#FF6666;"}
-   Discontinuation of study drugs due to intolerance
-   Hospitalization due to HF
-   DVT or PTE, PAD revascularization
-   Aortic intervention or surgery
-   Cataract operation
-   New-onset DM, ESRD
-   Composite of laboratory abnormalities

# [Statistical anaylsis]{style="color:navy;"}

## [Sample size calculation]{style="color:#FF6666;"}
- Based on previous studies<br> Expected event rate of primary endpoint: 4% per year
- Assuming two strategies have equivalent efficacy
- Non-inferioiriity margin was set at 3.0%
- 80% power, 2.5% one-sided alpha, 15% loss <br>-> _4400 required_

## [Procedure]{style="color:#FF6666;"}
<img src="studydesign.png"/>

## [Statistical analysis]{style="color:#FF6666;"}

-   Categorical data: numbers(percentages)
-   Continuous data: mean (SD) or median (IQR)

## [Statistical analysis]{style="color:#FF6666;"}
-   Incidence of primary endpoint: Kaplan-Meier method
-   Com-Nogue approach to estimate z statistics with Greenwood formula
-   When upper boud of one-sided 97.5% CI \< 3.0%, non-inferiority is established

## [Statistical analysis]{style="color:#FF6666;"}
<img src="comnogue.png"/>
<img src="greenwood.png"/>

## [Statistical analysis]{style="color:#FF6666;"}
-   Subgroup analysis: age, sex, BMI, HT, DM, CKD, baseline LDL-C, clinical presentation at randomization

# [Results]{style="color:navy;"}

## [Baseline characteristic]{style="color:#FF6666;"}

<img src="baseline.png"/>

## [Statin-Intensity]{style="color:#FF6666;"}
<img src="statinprofile.png"/>

## [Changes in LDL-C]{style="color:#FF6666;"}
<img src="ldlchange.png"/>

## [Primary endpoint(ITT)]{style="color:#FF6666;"}
<img src="primaryendpoint.png"/>

## [Primary endpoint(ITT)]{style="color:#FF6666;"}
- 8.1% vs 8.7%(p<0.001 for non-inferiority)
- All-cause death, MI, stroke did not differ statistically either
- Per-protocol analysis showed consistent result

## [Secondary endpoint]{style="color:#FF6666;"}<br>
- Secondary endpoint showed **no significant difference** <br>

## [Post-hoc analysis]{style="color:#FF6666;"}<br>
- Composite of new-onset DM, ESRD, CK,AST,ALT elevation _was lower in treat-to-target group_

## [Subgroup analysis]{style="color:#FF6666;"}
<img src="subgroup.png"/>

## [Other analysis: Reasons for discontinue]{style="color:#FF6666;"}
<img src="discontinue.png"/>


## [Discussion]{style="color:#FF6666;"}
- Lower proportion(around60%) of participants <br> with LDL-C<70 mg/dL <br>
-> Absence of recommendation of combination therapy <br>
-> Combination therapy was not frequently used <br>
-> Patient's reluctance to add more drugs 

## [Discussion]{style="color:#FF6666;"}

### Treat-to-target therapy 
- Accounts for individual therapeutic response to statin
- Numerically lower rate of secondary endpoint
- Significantly lower rate of composite of secondary endpoint

## [Discussion]{style="color:#FF6666;"}
- Validity of the target for CAD patients needs to be confirmed
- LDL-C level was higher early in target-to-treat-group<br>
-> Statin-naive patients started with moderate-intensity statin regardless of baseline LDL-C level
- Initial intensity needs to be selected according to baseline LDL-C level

## [Limits]{style="color:#FF6666;"}
- Open-label design
- Lower event rates than anticipated
- Comparison of primary endpoint was difficult due to small number of events
- Trial exclusively recruited patients with CAD
- Lower proportion of patients with LDL-C<70 mg/dL
- Relatively short follow-up period(3 months)